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Mycobacterium avium subsp. paratuberculosis is a slowly growing mycobacterial species, requiring 6 to 8 weeks
of culture before colonies can be counted visually. Here, we describe the development of luminescent M. avium
subsp. paratuberculosis expressing luxAB genes of Vibrio harveyi and its use for vaccine testing in an experi-
mental mouse model, replacing fastidious CFU counting by rapid luminometry.
Experimental Mycobacterium avium subsp. paratuberculosis
infection and vaccination studies are seriously hampered by
technical problems. M. avium subsp. paratuberculosis is a
slowly growing mycobacterial species, requiring 6 to 8 weeks
of culture before colonies can be counted visually. Deter-
mining the number of CFU in organ homogenates requires
labor-intensive plating on expensive mycobactin-supple-
mented Middlebrook agar (5). Here, we report on the con-
struction of two luminescent M. avium subsp. paratubercu-
losis isolates: i.e., reference strain ATCC 19698 (7) and
strain S-23, a clinical isolate of bovine origin (4). We show,
in an experimental mouse model, that rapid and cheap lu-
minometry can replace fastidious CFU enumeration on
agar, and furthermore we demonstrate that luminescent M.
avium subsp. paratuberculosis ATCC 19698 can be used for
the rapid screening of potential new paratuberculosis vac-
cine candidates.
We have previously reported on the use of pYUB180-trans-
formed M. avium subsp. paratuberculosis strain K-10 encoding
Photinus pyralis luciferase for antimicrobial drug susceptibility
testing (12). However, attempts to use this firefly luciferase-
expressing K-10 isolate for in vivo testing in an experimental
mouse model were unsuccessful, because of the low sensitivity
of the Turner Design 20/20 luminometer (10) (our unpublished
data). Based on our earlier experience with luminescent My-
cobacterium tuberculosis H37Rv (3, 11), encoding bacterial
luxAB genes from Vibrio harveyi, we decided to use the same
approach for M. avium subsp. paratuberculosis. M. avium subsp.
paratuberculosis reference strain ATCC 19698 and strain S-23
were transformed as described previously (12) with plasmid
pSMT1 encoding luxAB genes downstream from the Mycobac-
terium bovis BCG hsp60 promoter and a hygromycin resistance
gene as a selectable marker (10). pSMT1 DNA was prepared
in Escherichia coli with a Wizard Miniprep kit (Promega, Mad-
ison, WI). Transformants were grown at 37°C for 5 weeks on
Middlebrook 7H9 agar supplemented with OADC (oleic acid,
albumin, dextrose, and catalase), mycobactin J (Allied Labo-
ratories Inc., Synbiotics Europe) (2 g/ml), and 50 g/ml hy-
gromycin. This is the first report on the use of this drug marker
to select M. avium subsp. paratuberculosis transformants.
Transformed, luminescent M. avium subsp. paratuberculosis
ATCC 19698 or S-23 was grown in Middlebrook 7H9 medium
supplemented with OADC, mycobactin J, and hygromycin, to
an optical density of 0.6. Bacteria were washed in phosphate-
buffered saline (PBS), and the number of bioluminescent bac-
teria was determined using a bioluminescence assay in a
Turner Design 20/20 luminometer with 1% n-decyl-aldehyde
(Sigma) and ethanol as a substrate (11). Compared to a clas-
sical firefly luciferase-based test, this bacterial luciferase-based
assay has the economical advantage of combining a low-price
luminometer with an inexpensive substrate. In this assay, only
live bacteria are enumerated, as light emission is dependent on
the presence of reduced flavin mononucleotide (FMNH2), a
cofactor only found in living cells. Female BALB.B10 mice
(bred at the Animal Facilities of the Pasteur Department) were
infected intravenously in a lateral tail vein with 0.2 ml of
bacteria, adjusted to 2  106 milli-relative light units (mRLU)/
ml. The number of CFU of these preparations, determined by
plating serial dilutions in PBS on Middlebrook 7H11-OADC
agar supplemented with mycobactin J and hygromycin (100
g/ml), was 5  106 CFU/ml. Thus, the CFU/mRLU ratio for
axenic M. avium subsp. paratuberculosis cultures was 2.5. This
ratio is a relative value specific for each laboratory and depen-
dent on the type of luminometer used. The number of bacteria
in spleen homogenates of individual infected mice was deter-
mined 5, 10, and 15 weeks after infection. Mice were killed by
cervical dislocation, and spleens were removed aseptically and
homogenized in 10 ml of PBS using a loosely fitting Dounce
homogenizer (8). For luminometry, fresh 1-ml spleen homog-
enates were tested in duplicate after erythrocyte lysis (to min-
imize quenching) as described previously (11). For CFU plat-
ing, 100-l volumes of serial dilutions of spleen homogenate in
PBS were plated in duplicate on Middlebrook 7H11-OADC
agar supplemented with mycobactin J. To check for the pres-
ence or loss of the pSMT1 plasmid, platings were performed in
media with (h) or without hygromycin (100 g/ml). Petri dishes
were sealed in plastic bags and incubated at 39°C for 8 weeks
before visual counting. For all statistical analyses (Student’s t
test), luminometry results obtained in mRLU and plating re-
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sults obtained in CFU were converted to mean log10 values/
total spleen.
As shown in Table 1, both luminescent M. avium subsp.
paratuberculosis strains could be detected in the spleens of
infected BALB.B10 mice by luminometry and CFU plating
throughout the entire 15-week follow-up period. Intravenous
infection of seven inbred mouse strains with luminescent M.
avium subsp. paratuberculosis showed that genetic susceptibil-
ity to M. avium subsp. paratuberculosis infection was controlled
by Nramp1 (9), with BALB.B10 mice displaying a susceptible
phenotype (V. Rosseels et al., unpublished data). The S-23
clinical strain (kept with a low number of in vitro passages) was
somewhat more virulent in this mouse model than was the
ATCC 19698 strain (dating back to 1979), as both luminometry
and CFU plating of S-23 showed a modest increase in bacterial
number in the spleens of BALB.B10 mice between weeks 5 and
15 after infection, whereas bacterial numbers of the ATCC
19698 strain remained constant over the 15-week test period.
The numbers of CFU of M. avium subsp. paratuberculosis
ATCC 19698 determined with or without hygromycin were
identical at the three time points tested, whereas the lumines-
cent S-23 strain showed a tendency to lose the pSMT1 plasmid,
resulting in 0.41 and 0.51 log10 less CFU at weeks 10 and 15,
respectively, in 7H11 agar supplemented with hygromycin than
in agar without hygromycin. The CFU/mRLU ratios of these
ex vivo-isolated mycobacteria were 35.5 for ATCC 19698 and
34.7 for S-23 after 5 weeks of infection. These ratios were
about 15-fold higher than that for in vitro-grown M. avium
subsp. paratuberculosis and can be explained by light quenching
effects and by reduced fitness of the bacteria isolated from the
harsh environment of the macrophage phagosome. A similar
difference in CFU/mRLU ratio has been observed for in vitro-
grown and ex vivo-isolated luminescent M. tuberculosis H37Rv
(K. Huygen, unpublished data). The luciferase-based assay had
two advantages over classical CFU plating in addition to its
rapidity and inexpensiveness. The luminescence assay on du-
plicate samples was very reproducible, with 5 to 10% intra-
assay variation. CFU counting was less accurate, with intra-
TABLE 2. Protective efficacy of irradiated M. avium subsp. paratuberculosis and M. bovis BCG vaccines, as tested by luminometry
and CFU plating of spleen cell homogenatesa
Wk after
infection
No. of bacteria in spleenb
Unvaccinated
Irradiated M. avium subsp.
paratuberculosis M. bovis BCG
Count c Count 
5
Log10 mRLU 4.06  0.30 (3) 3.44  0.23 (5)* 0.62 3.06  0.08 (3)**‡ 1
Log10 mCFU (h) 5.58  0.31 (3) 5.21  0.31 (5)† 0.37 5.08  0.23 (3)† 0.50
Log10 mCFU 5.54  0.26 (3) 5.22  0.30 (5)† 0.32 5.08  0.17 (3)† 0.46
10
Log10 mRLU 3.87  0.11 (3) 3.22  0.14 (5)*** 0.65 3.03  0.07 (3)*** 0.84
Log10 mCFU (h) 5.47  0.17 (3) 5.13  0.17 (4)* 0.34 4.88  0.28 (3)* 0.59
Log10 mCFU 5.49  0.22 (3) 5.24  0.14 (4)† 0.25 4.91  0.31 (3)† 0.58
15
Log10 mRLU 3.78  0.07 (3) 3.57  0.24 (5)† 0.21 3.12  0.08 (4)***‡ 0.66
Log10 mCFU (h) 5.41  0.26 (3) 4.83  0.30 (5)* 0.58 4.64  0.12 (4)** 0.7
Log10 mCFU 5.45  0.18 (3) 4.82  0.36 (4)* 0.63 4.61  0.06 (3)** 0.84
a BALB.B10 mice were sacrificed 5, 10, or 15 weeks after intravenous M. avium subsp. paratuberculosis infection, and the number of bacteria in the spleen
was determined in individual spleen homogenates by luminometry (log10 mRLU) or CFU plating on Middlebrook 7H11 agar supplemented with hygromycin (h)
or not supplemented.
b The number of mice is given in parentheses. P values calculated using Student’s t test, compared to the number of bacteria in unvaccinated mice, are indicated as
follows: †, not significant; *, 0.01  P  0.05; **, 0.001  P  0.01; and ***, P  0.001. ‡, P value of 0.05 compared to the number of bacteria in mice vaccinated
with irradiated M. avium subsp. paratuberculosis.
c   log10 mRLUCFU(h), CFU	 unvaccinated 
 log10 mRLUCFU(h), CFU	 vaccinated.
TABLE 1. Bacterial replication of luminescent M. avium subsp. paratuberculosis ATCC 19698 and S-23 in spleens from BALB.B10 mice,
analyzed 5, 10, and 15 weeks postinfectiona
Wk after
infection
Bacterial countb
ATCC 19698 S-23
Log10 mRLU Log10 CFU (h) Log10 CFU Log10 mRLU Log10 CFU (h) Log10 CFU
5 4.06  0.30 5.61  0.29 5.61  0.26 A 4.01  0.15 5.46  0.14 5.55  0.09 A
10 3.87  0.11 C 5.42  0.19 C 5.44  0.26 AC 4.35  0.27 C 5.59  0.07 C 5.90  0.15 BD
15 3.78  0.07 C 5.42  0.12 C 5.46  0.09 AC 4.31  0.04 D 5.63  0.14 C 6.14  0.21 BD
a Spleens from individual infected mice (n  3/group) were homogenized, and the number of bacteria/spleen was enumerated by luminometry (results in mRLU
converted to log10) or by CFU plating on Middlebrook 7H11 agar supplemented with hygromycin (h) or not supplemented.
b P values that represent probabilities compared to log10 CFU (h) values, calculated using Student’s t test, are indicated as follows: A, not significant; B, P  0.05.
P values that represent probabilities compared to the number of bacteria on week 5, as calculated using Student’s t test, are indicated as follows: C, not significant; D,
P  0.05.
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assay variations between 10 to 25%. Also, the detection
window for luminometry was much wider, ranging between 102
and 107 mRLU, whereas precise CFU counting was possible
only for 10 to 100 CFU/petri dish, requiring a series of spleen
homogenate dilutions.
In order to validate the model for vaccine screening, we
applied this luminometric technology to compare the protec-
tive efficacies as vaccines of -irradiated M. avium subsp. para-
tuberculosis ATCC 19698 and the live M. bovis BCG vaccine
used against bovine (2) and human (1) tuberculosis. M. avium
subsp. paratuberculosis ATCC 19698 was grown for 2 weeks as
a surface pellicle on synthetic mycobactin J-supplemented Sau-
ton medium and -irradiated with 0.5 megarads (IBA Mediris,
Fleurus, Belgium). Female BALB.B10 mice were vaccinated
subcutaneously with 0.5 mg (wet weight) of irradiated M.
avium subsp. paratuberculosis ATCC 19698 in Montanide ISA
775 (SEPPIC) adjuvant or intravenously in a lateral tail vein
with 0.5 mg (2  106 CFU) of BCG and challenged 20 weeks
later by the intravenous route with 0.2 ml of luminescent M.
avium subsp. paratuberculosis. The challenge was performed
with the reference ATCC 19698 strain (4  105 mRLU/
mouse), which had demonstrated 100% stability of its pSMT1
plasmid. As shown in Table 2, BALB.B10 mice immunized
with irradiated M. avium subsp. paratuberculosis vaccine or live
M. bovis BCG demonstrated significantly reduced bacterial
counts after challenge compared to unvaccinated mice. BCG
vaccine appeared to be slightly more effective than irradiated
M. avium subsp. paratuberculosis, but the difference was statis-
tically significant in luminometry only at week 5 and week 15
after challenge. At the first two time points after challenge,
luminometry was more sensitive for detecting vaccine efficacy
than for CFU counting. Thus, at week 5 after challenge, BCG
vaccine resulted in a 10-fold reduction (1 log10) in mRLU
counts, whereas CFU values were reduced only threefold (0.5
log10). This difference between the two assays could not be
explained by loss of plasmid, as there was no difference in the
numbers of bacteria grown with or without hygromycin. Com-
paring mRLU and CFU (h) values in unvaccinated mice, CFU/
mRLU ratios of 33, 40, and 42 were found at 5, 10, and 15
weeks after infection, respectively. For mice vaccinated with
irradiated M. avium subsp. paratuberculosis, these differences
were 59, 81, and 18; and finally for mice vaccinated with live
BCG, CFU/mRLU ratios were 105, 71, and 33. These different
CFU/mRLU ratios in vaccinated and unvaccinated mice sug-
gest that at least at the first two time points, the overall fitness
of the bacteria was more impaired in the vaccinated than in the
unvaccinated groups. We hypothesize that the luciferase-based
assay could actually detect not only differences in numbers of
bacteria but also differences in their metabolic activity. The
latter would result in bacterial colonies of smaller sizes, which
is technically very difficult to demonstrate for M. avium subsp.
paratuberculosis, in view of its extremely low multiplication
rate.
In conclusion, our results show that luminescent M. avium
subsp. paratuberculosis transformed with pSMT1 plasmid en-
coding the luxAB genes of Vibrio harveyi may be a valuable tool
for the rapid, simple, and cheap in vivo screening of vaccine
candidates. Moreover, these luminescent bacteria could also
be used for in vitro drug testing and in vitro monitoring of
bacterial replication in cell lines such as bovine epithelial cells.
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